Literature DB >> 12506973

Cloned cytosine deaminase gene expression of Bifidobacterium longum and application to enzyme/pro-drug therapy of hypoxic solid tumors.

Toshiyuki Nakamura1, Takayuki Sasaki, Minoru Fujimori, Kazuyuki Yazawa, Yasunobu Kano, Jun Amano, Shun'ichiro Taniguchi.   

Abstract

Bifidobacterium longum is a nonpathogenic anaerobic bacterium among normal bacterial flora. Recently, it was reported that B. longum accumulated in hypoxic solid tumors. The gene of interest was expressed in transfected B. longum by the shuttle vector pBLES100 in solid tumors. In this report, we constructed pBLES100-S-eCD, which included the cytosine deaminase gene. We confirmed by western blotting that transfected B. longum produced cytosine deaminase. In addition, transfected B. longum produced cytosine deaminase that converted 5-fluorocytosine into 5-fluorouracil. B. longum could be useful for enzyme/pro-drug therapy of hypoxic solid tumors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12506973     DOI: 10.1271/bbb.66.2362

Source DB:  PubMed          Journal:  Biosci Biotechnol Biochem        ISSN: 0916-8451            Impact factor:   2.043


  19 in total

1.  Bifidobacteria can protect from enteropathogenic infection through production of acetate.

Authors:  Shinji Fukuda; Hidehiro Toh; Koji Hase; Kenshiro Oshima; Yumiko Nakanishi; Kazutoshi Yoshimura; Toru Tobe; Julie M Clarke; David L Topping; Tohru Suzuki; Todd D Taylor; Kikuji Itoh; Jun Kikuchi; Hidetoshi Morita; Masahira Hattori; Hiroshi Ohno
Journal:  Nature       Date:  2011-01-27       Impact factor: 49.962

2.  Sequence analysis of two cryptic plasmids from Bifidobacterium longum DJO10A and construction of a shuttle cloning vector.

Authors:  Ju-Hoon Lee; Daniel J O'Sullivan
Journal:  Appl Environ Microbiol       Date:  2006-01       Impact factor: 4.792

3.  Tough nuts to crack: site-directed mutagenesis of bifidobacteria remains a challenge.

Authors:  Vincenzo F Brancaccio; Daria S Zhurina; Christian U Riedel
Journal:  Bioengineered       Date:  2013-01-11       Impact factor: 3.269

4.  Orally administered bifidobacteria as vehicles for delivery of agents to systemic tumors.

Authors:  Michelle Cronin; David Morrissey; Simon Rajendran; Shereen M El Mashad; Douwe van Sinderen; Gerald C O'Sullivan; Mark Tangney
Journal:  Mol Ther       Date:  2010-04-13       Impact factor: 11.454

Review 5.  Bacteria as vectors for gene therapy of cancer.

Authors:  Chwanrow K Baban; Michelle Cronin; Deirdre O'Hanlon; Gerald C O'Sullivan; Mark Tangney
Journal:  Bioeng Bugs       Date:  2010 Nov-Dec

Review 6.  Microbial-based therapy of cancer: current progress and future prospects.

Authors:  Nuno Bernardes; Raquel Seruca; Ananda M Chakrabarty; Arsenio M Fialho
Journal:  Bioeng Bugs       Date:  2009-12-02

7.  Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104.

Authors:  Shie-Chau Liu; G-One Ahn; Mitomu Kioi; Mary-Jo Dorie; Adam V Patterson; J Martin Brown
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

8.  Therapeutic efficacy of Bifidobacterium longum-mediated human interleukin-2 with endostatin or TRAIL in transplanted tumors in mice.

Authors:  Yan Yin; Lei Kou; Jian-Jun Wang; Gen-Xing Xu
Journal:  Exp Ther Med       Date:  2011-12-19       Impact factor: 2.447

9.  Molecular dissection of a bifidobacterial replicon.

Authors:  Michelle Cronin; Moritz Knobel; Mary O'Connell-Motherway; Gerald F Fitzgerald; Douwe van Sinderen
Journal:  Appl Environ Microbiol       Date:  2007-10-26       Impact factor: 4.792

Review 10.  Engineering the gut microbiota to treat chronic diseases.

Authors:  Noura S Dosoky; Linda S May-Zhang; Sean S Davies
Journal:  Appl Microbiol Biotechnol       Date:  2020-07-21       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.